Tenax Therapeutics (NASDAQ:TENX) issued its quarterly earnings results on Thursday. The specialty pharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.38) by $0.05, Fidelity Earnings reports.
Shares of TENX opened at $1.15 on Friday. The firm has a market cap of $7.75 million, a PE ratio of -0.13 and a beta of 1.37. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.05 and a current ratio of 10.05. The business’s 50 day moving average price is $1.22 and its two-hundred day moving average price is $1.32. Tenax Therapeutics has a 52-week low of $1.03 and a 52-week high of $5.12.
Separately, ValuEngine raised Tenax Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st.
Tenax Therapeutics, Inc, a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome.
Read More: Guidelines for Successful Channel Trading
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.